Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 216018
Company: SPIL
Company: SPIL
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
ASPRUZYO SPRINKLE | RANOLAZINE | 500MG | GRANULES, EXTENDED RELEASE;ORAL | Discontinued | None | Yes | No |
ASPRUZYO SPRINKLE | RANOLAZINE | 1GM | GRANULES, EXTENDED RELEASE;ORAL | Discontinued | None | Yes | No |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
02/28/2022 | ORIG-1 | Approval | Type 3 - New Dosage Form | STANDARD |
Label (PDF)
Letter (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216018s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/216018Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/216018Orig1s000TOC.cfm |
Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
---|---|---|---|---|---|
02/28/2022 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216018s000lbl.pdf |